(RTTNews) - Biodexa Pharmaceuticals PLC (BDRX) announced the appointment of Gary Shangold as Chief Medical Officer with immediate effect. Most recently, Shangold was Chief Medical Officer of Enteris BioPharma, a wholly owned subsidiary of SWK Holdings Corporation.
Stephen Stamp, CEO and CFO of Biodexa said: "As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists with Garys knowledge and experience. I have worked with Gary before at Xanodyne where he was instrumental in securing two NDAs."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
